Global expansion Crystal Pharmatech has recently expanded facilities to New Jersey, Ontario, and Suzhou, showcasing growing capacity for GMP manufacturing and preformulation work that can support larger client programs and regional partnerships.

Integrated solid-state leadership The company emphasizes end-to-end solid-state science from screening to manufacturing with a single scientific team, enabling faster project handoffs and First-Time-Right execution which reduces cycle times for clients with solid form and solubility challenges.

Advanced solubility capabilities Expertise in amorphous solid dispersions via spray drying and hot-melt extrusion positions Crystal Pharmatech to capture opportunities in poorly soluble molecules, PROTACs, oral peptides, and other nontraditional chemical spaces.

Strategic collaborations Recent partnerships with Divamics and ELDICO Scientific, plus ongoing collaboration prospects, indicate a growing ecosystem around AI-driven discovery and advanced analytical capabilities that can enhance CRO/CDMO offerings for customers seeking integrated solutions.

Security and risk Ransomware incident noted in 2026 highlights the importance of robust cybersecurity and data protection services; buyers may seek enhanced cybersecurity, data governance, and contingency planning as part of vendor selection and ongoing risk management.